Posted by on June 15, 2018 2:51 pm
Tags:
Categories: CRISPR-Google

Source: Why reports about CRISPR'd cells and cancer aren't calamitous — but shouldn't be ignored

S

TAT’s story about CRISPR-edited cells often lacking a functional gene known to prevent cancer caused a bit of a stir. On Wall Street, some investors dumped shares of Editas Medicine, CRISPR Therapeutics, and Intellia (the three pure-CRISPR plays; other companies are pursuing other forms of genome-editing). Social media delivered the expected blowback, apparently because we dared to raise the possibility that it might possibly be necessary to test possibly CRISPR’d cells for possible cancer-causing changes. We’re doing an online chat about all this next week, but in case you can’t wait:

Cut to the chase: Is this the death knell for CRISPR? No. Not even close.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What’s included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Published at Fri, 15 Jun 2018 08:49:24 +0000